Lipoprotein-associated phospholipase A2 decreases oxidized lipoprotein cellular association by human macrophages and hepatocytes

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1801, Issue 2, 2010, Pages 176-182

  Yang, Ming ^a   Chu, Eugene M ^a   Caslake, Muriel J ^b   Edelstein, Celina ^c   Scanu, Angelo M ^c   Hill, John S ^a  

^a The James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research   (Canada)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

HepG2; Lipoprotein(a); Lipoprotein associated phospholipase A2; Macrophage; Oxidized LDL; Platelet activating factor acetylhydrolase

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; LIPOPROTEIN A; LYSOPHOSPHATIDYLCHOLINE; OXIDIZED LIPOPROTEIN A; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED PHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYDROLYSIS; LIVER CELL; MACROPHAGE; PRIORITY JOURNAL;

CELLS, CULTURED; FLOW CYTOMETRY; HEPATOCYTES; HUMANS; LIPOPROTEIN(A); LIPOPROTEINS, LDL; MACROPHAGES; MONOCYTES; PHOSPHOLIPASES A2; RECOMBINANT PROTEINS;

EID: 74049135494     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2009.10.011     Document Type: Article

References (34)

1. Gorelick P.B. Lipoprotein-associated phospholipase A2 and risk of stroke. Am. J. Cardiol. 101 (2008) 34F-40F
2. Anderson J.L. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Am. J. Cardiol. 101 (2008) 23F-33F
3. Serruys P.W., Garcia-Garcia H.M., Buszman P., Erne P., Verheye S., Aschermann M., Duckers H., Bleie O., Dudek D., Botker H.E., von Birgelen C., D'Amico D., Hutchinson T., Zambanini A., Mastik F., van Es G.A., van der Steen A.F., Vince D.G., Ganz P., Hamm C.W., Wijns W., and Zalewski A. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 118 (2008) 1172-1182
4. Tellis C.C., and Tselepis A.D. Tauhe role of lipoprotein-associated phospholipase A(2) in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim. Biophys. Acta 1791 (2009) 327-338
5. Kolodgie F.D., Burke A.P., Skorija K.S., Ladich E., Kutys R., Makuria A.T., and Virmani R. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 2523-2529
6. Min J.H., Wilder C., Aoki J., Arai H., Inoue K., Paul L., and Gelb M.H. Platelet-activating factor acetylhydrolases: broad substrate specificity and lipoprotein binding does not modulate the catalytic properties of the plasma enzyme. Biochemistry 40 (2001) 4539-4549
7. Witztum J.L., and Berliner J.A. Oxidized phospholipids and isoprostanes in atherosclerosis. Curr. Opin. Lipidol. 9 (1998) 441-448
8. Gillotte K.L., Horkko S., Witztum J.L., and Steinberg D. Oxidized phospholipids, linked to apolipoprotein B of oxidized LDL, are ligands for macrophage scavenger receptors. J. Lipid Res. 41 (2000) 824-833
9. Boullier A., Gillotte K.L., Horkko S., Green S.R., Friedman P., Dennis E.A., Witztum J.L., Steinberg D., and Quehenberger O. The binding of oxidized low density lipoprotein to mouse CD36 is mediated in part by oxidized phospholipids that are associated with both the lipid and protein moieties of the lipoprotein. J. Biol. Chem. 275 (2000) 9163-9169
10. Matsumoto T., Kobayashi T., and Kamata K. Role of lysophosphatidylcholine (LPC) in atherosclerosis. Curr. Med. Chem. 14 (2007) 3209-3220
11. Fuki I.V., Blanchard N., Jin W., Marchadier D.H., Millar J.S., Glick J.M., and Rader D.J. Endogenously produced endothelial lipase enhances binding and cellular processing of plasma lipoproteins via heparan sulfate proteoglycan-mediated pathway. J. Biol. Chem. 278 (2003) 34331-34338
12. Merkel M., Kako Y., Radner H., Cho I.S., Ramasamy R., Brunzell J.D., Goldberg I.J., and Breslow J.L. Catalytically inactive lipoprotein lipase expression in muscle of transgenic mice increases very low density lipoprotein uptake: direct evidence that lipoprotein lipase bridging occurs in vivo. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 13841-13846
13. Jurgens G., Hoff H.F., Chisolm III G.M., and Esterbauer H. Modification of human serum low density lipoprotein by oxidation-characterization and pathophysiological implications. Chem. Phys. Lipids 45 (1987) 315-336
14. Suits A.G., Chait A., Aviram M., and Heinecke J.W. Phagocytosis of aggregated lipoprotein by macrophages: low density lipoprotein receptor-dependent foam-cell formation. Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 2713-2717
15. Fless G.M., Snyder M.L., Furbee Jr. J.W., Garcia-Hedo M.T., and Mora R. Subunit composition of lipoprotein(a) protein. Biochemistry 33 (1994) 13492-13501
16. Schumaker V.N., and Puppione D.L. Sequential flotation ultracentrifugation. Methods Enzymol. 128 (1986) 155-170
17. Kishimoto T., Soda Y., Matsuyama Y., and Mizuno K. An enzymatic assay for lysophosphatidylcholine concentration in human serum and plasma. Clin. Biochem. 35 (2002) 411-416
18. Saougos V.G., Tambaki A.P., Kalogirou M., Kostapanos M., Gazi I.F., Wolfert R.L., Elisaf M., and Tselepis A.D. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 2236-2243
19. Dentan C., Tselepis A.D., Chapman M.J., and Ninio E. Pefabloc, 4-[2-aminoethyl]benzenesulfonyl fluoride, is a new, potent nontoxic and irreversible inhibitor of PAF-degrading acetylhydrolase. Biochim. Biophys. Acta 1299 (1996) 353-357
20. Wooton-Kee C.R., Boyanovsky B.B., Nasser M.S., de Villiers W.J., and Webb N.R. Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 762-767
21. Hakala J.K., Oorni K., Ala-Korpela M., and Kovanen P.T. Lipolytic modification of LDL by phospholipase A2 induces particle aggregation in the absence and fusion in the presence of heparin. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 1276-1283
22. Oorni K., Hakala J.K., Annila A., Ala-Korpela M., and Kovanen P.T. Sphingomyelinase induces aggregation and fusion, but phospholipase A2 only aggregation, of low density lipoprotein (LDL) particles. Two distinct mechanisms leading to increased binding strength of LDL to human aortic proteoglycans. J. Biol. Chem. 273 (1998) 29127-29134
23. Murugesan G., and Fox P.L. Role of lysophosphatidylcholine in the inhibition of endothelial cell motility by oxidized low density lipoprotein. J. Clin. Invest. 97 (1996) 2736-2744
24. Meyer D.F., Nealis A.S., Macphee C.H., Groot P.H., Suckling K.E., Bruckdorfer K.R., and Perkins S.J. Time-course studies by synchrotron X-ray solution scattering of the structure of human low-density lipoprotein during Cu(2+)-induced oxidation in relation to changes in lipid composition. Biochem. J. 319 Pt 1 (1996) 217-227
25. Davis B., Koster G., Douet L.J., Scigelova M., Woffendin G., Ward J.M., Smith A., Humphries J., Burnand K.G., Macphee C.H., and Postle A.D. Electrospray ionization mass spectrometry identifies substrates and products of lipoprotein-associated phospholipase A2 in oxidized human low density lipoprotein. J. Biol. Chem. 283 (2008) 6428-6437
26. Asatryan L., Hamilton R.T., Isas J.M., Hwang J., Kayed R., and Sevanian A. LDL phospholipid hydrolysis produces modified electronegative particles with an unfolded apoB-100 protein. J. Lipid Res. 46 (2005) 115-122
27. de Rijke Y.B., Jurgens G., Hessels E.M., Hermann A., and van Berkel T.J. In vivo fate and scavenger receptor recognition of oxidized lipoprotein[a] isoforms in rats. J. Lipid Res. 33 (1992) 1315-1325
28. Turunen P., Puhakka H., Rutanen J., Hiltunen M.O., Heikura T., Gruchala M., and Yla-Herttuala S. Intravascular adenovirus-mediated lipoprotein-associated phospholipase A2 gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Atherosclerosis 179 (2005) 27-33
29. Ky B., Burke A., Tsimikas S., Wolfe M.L., Tadesse M.G., Szapary P.O., Witztum J.L., FitzGerald G.A., and Rader D.J. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J. Am. Coll. Cardiol. 51 (2008) 1653-1662
30. Vickers K.C., Maguire C.T., Wolfert R., Burns A.R., Reardon M., Geis R., Holvoet P., and Morrisett J.D. Relationship of lipoprotein-associated phospholipase A2 and oxidized low-density lipoprotein in carotid atherosclerosis. J. Lipid Res. 50 (2009) 1735-1743
31. Aoyama T., Fujiwara H., Masaki T., and Sawamura T. Induction of lectin-like oxidized LDL receptor by oxidized LDL and lysophosphatidylcholine in cultured endothelial cells. J. Mol. Cell. Cardiol. 31 (1999) 2101-2114
32. Aoyama T., Chen M., Fujiwara H., Masaki T., and Sawamura T. LOX-1 mediates lysophosphatidylcholine-induced oxidized LDL uptake in smooth muscle cells. FEBS Lett. 467 (2000) 217-220
33. Chang M.Y., Tsoi C., Wight T.N., and Chait A. Lysophosphatidylcholine regulates synthesis of biglycan and the proteoglycan form of macrophage colony stimulating factor. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 809-815
34. Williams K.J., and Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 15 (1995) 551-561